tunlametinib + vemurafenib

Tunlametinib (HL-085) plus vemurafenib is a combination therapy under investigation for the treatment of advanced solid tumors harboring BRAF V600 mutations, including melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer. Tunlametinib is a novel, highly selective MEK inhibitor that blocks the MAPK/ERK pathway downstream of BRAF. Vemurafenib is an orally available small molecule inhibitor targeting mutated BRAF-serine-threonine kinase, particularly effective against the BRAF V600E mutation. The combination aims to provide dual blockade of the MAPK pathway at both MEK and BRAF nodes to enhance antitumor activity and overcome resistance mechanisms seen with monotherapy. Clinical studies have shown promising efficacy and manageable safety in patients who have progressed on or are intolerant to standard therapies[1][2][3][5][7].

Brand names

Zelboraf

Other names

HL-085 + vemurafenibtunlametinib + vemurafenib